Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 10, Pages 5207
Publisher
MDPI AG
Online
2021-05-14
DOI
10.3390/ijms22105207
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy
- (2020) Carly Bess Williams et al. BREAST CANCER RESEARCH AND TREATMENT
- Copanlisib for the treatment of adults with relapsed follicular lymphoma
- (2020) Massimo Magagnoli et al. Expert Review of Clinical Pharmacology
- 568P Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours
- (2020) I. Colombo et al. ANNALS OF ONCOLOGY
- LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
- (2020) D.W. Miles et al. ANNALS OF ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Mechanisms of immune evasion in breast cancer
- (2018) Joshua P. Bates et al. BMC CANCER
- Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
- (2018) Ricardo L. B. Costa et al. BREAST CANCER RESEARCH AND TREATMENT
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
- (2018) Larissa S. Carnevalli et al. Journal for ImmunoTherapy of Cancer
- Neutrophils in Homeostasis, Immunity, and Cancer
- (2017) José Ángel Nicolás-Ávila et al. IMMUNITY
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
- (2017) Woosung Chung et al. Nature Communications
- Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
- (2017) Floriana Morgillo et al. Oncotarget
- PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
- (2016) Jiqing Sai et al. CLINICAL CANCER RESEARCH
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- Benefit Mixed with Caution for Buparlisib
- (2016) Cancer Discovery
- The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis
- (2015) Lisa M. Ooms et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
- (2013) Matthew J. Ellis et al. Cancer Discovery
- Isolation, Purification and Labeling of Mouse Bone Marrow Neutrophils for Functional Studies and Adoptive Transfer Experiments
- (2013) Muthulekha Swamydas et al. Jove-Journal of Visualized Experiments
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
- (2011) Michael C. Schmid et al. CANCER CELL
- Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
- (2011) R. Mallon et al. CLINICAL CANCER RESEARCH
- Phenotype, Function, and Gene Expression Profiles of Programmed Death-1 hi CD8 T Cells in Healthy Human Adults
- (2011) Jaikumar Duraiswamy et al. JOURNAL OF IMMUNOLOGY
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
- (2009) Zvi G. Fridlender et al. CANCER CELL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started